

Zhaoshi Bao

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9537634/zhaoshi-bao-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31
papers

1,094
citations

16
h-index

33
g-index

33
ext. papers

1,671
ext. citations

6.8
avg, IF

3.96
L-index

#	Paper	IF	Citations
31	CGCG clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2016 , 375, 263-273	9.9	253
30	Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. <i>Neuro-Oncology</i> , 2012 , 14, 1432-40	1	133
29	Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. <i>Cell</i> , 2018 , 175, 1665-1678.e18	56.2	125
28	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. <i>Genomics, Proteomics and Bioinformatics</i> , 2021 , 19, 1-12	6.5	103
27	Clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2021 , 499, 60-73.9	7.9	61
26	MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis. <i>Oncotarget</i> , 2014 , 5, 12908-15	3.3	48
25	MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas. <i>Nature Communications</i> , 2020 , 11, 3883	17.4	47
24	Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution. <i>Oncotarget</i> , 2015 , 6, 7318-24	3.3	33
23	Interplay between PCBP2 and miRNA modulates ARHGDI A expression and function in glioma migration and invasion. <i>Oncotarget</i> , 2016 , 7, 19483-98	3.3	32
22	BMP4, a strong better prognosis predictor, has a subtype preference and cell development association in gliomas. <i>Journal of Translational Medicine</i> , 2013 , 11, 100	8.5	27
21	KIF23 is an independent prognostic biomarker in glioma, transcriptionally regulated by TCF-4. <i>Oncotarget</i> , 2016 , 7, 24646-55	3.3	25
20	Identification of miRNA-mediated core gene module for glioma patient prediction by integrating high-throughput miRNA, mRNA expression and pathway structure. <i>PLoS ONE</i> , 2014 , 9, e96908	3.7	23
19	ALDH1A3: A Marker of Mesenchymal Phenotype in Gliomas Associated with Cell Invasion. <i>PLoS ONE</i> , 2015 , 10, e0142856	3.7	22
18	PTBP1 induces ADAR1 p110 isoform expression through IRES-like dependent translation control and influences cell proliferation in gliomas. <i>Cellular and Molecular Life Sciences</i> , 2015 , 72, 4383-97	10.3	20
17	SOCS3 promoter hypermethylation is a favorable prognosticator and a novel indicator for G-CIMP-positive GBM patients. <i>PLoS ONE</i> , 2014 , 9, e91829	3.7	19
16	Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas. <i>Oncotarget</i> , 2014 , 5, 7342-56	3.3	18
15	Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma. <i>Journal of Neurosurgery</i> , 2017 , 126, 249-259	3.2	15

14	CDC20 with malignant progression and poor prognosis of astrocytoma revealed by analysis on gene expression. <i>Journal of Neuro-Oncology</i> , 2017 , 133, 87-95	4.8	13
13	Hypomethylated Rab27b is a progression-associated prognostic biomarker of glioma regulating MMP-9 to promote invasion. <i>Oncology Reports</i> , 2015 , 34, 1503-9	3.5	13
12	relevant bioinformatic profiling and prognostic value in gliomas. <i>Future Oncology</i> , 2020 , 16, 4279-4288	3.6	11
11	Integrated analysis using methylation and gene expression microarrays reveals PDE4C as a prognostic biomarker in human glioma. <i>Oncology Reports</i> , 2014 , 32, 250-60	3.5	10
10	Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution. <i>Frontiers of Medicine</i> , 2021 , 15, 551-561	12	9
9	MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status. <i>Disease Markers</i> , 2018 , 2018, 5975216	3.2	8
8	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data for Chinese Glioma Patients		8
7	LINC00174 is a favorable prognostic biomarker in glioblastoma via promoting proliferative phenotype. <i>Cancer Biomarkers</i> , 2020 , 28, 421-427	3.8	6
6	Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling. <i>Aging</i> , 2018 , 10, 1977-1988	5.6	5
5	Is Relating With M2 Macrophage and Remarkable Malignancy Characters in Low-Grade Glioma. <i>Frontiers in Immunology</i> , 2021 , 12, 659659	8.4	4
4	Comprehensive transcriptomic characterization reveals core genes and module associated with immunological changes via 1619 samples of brain glioma. <i>Cell Death and Disease</i> , 2021 , 12, 1140	9.8	2
3	NCMP-28. PTPRZ1-MET SIGNALING PROMOTES GLIOMA PROGRESSION THROUGH STIMULATION THE TRANSFORMATION FROM M1 TO M2 MACROPHAGE. <i>Neuro-Oncology</i> , 2018 , 20, vi199-vi199	1	1
2	Comprehensive analysis of the LncRNAs, MiRNAs, and MRNAs acting within the competing endogenous RNA network of LGG.. <i>Genetica</i> , 2022 , 150, 41	1.5	0
1	Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.. <i>Radiotherapy and Oncology</i> , 2021 , 167, 1-6	5.3	0